Arcturus Current Deferred Revenue from 2010 to 2024
| ARCT Stock | USD 17.51 0.58 3.43% |
Current Deferred Revenue | First Reported 2017-12-31 | Previous Quarter 44.9 M | Current Value 26.9 M | Quarterly Volatility 19.8 M |
Check Arcturus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcturus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.1 M, Interest Expense of 530 K or Selling General Administrative of 55.5 M, as well as many indicators such as Price To Sales Ratio of 5.06, Dividend Yield of 0.0 or PTB Ratio of 3.17. Arcturus financial statements analysis is a perfect complement when working with Arcturus Therapeutics Valuation or Volatility modules.
Arcturus | Current Deferred Revenue |
Latest Arcturus Therapeutics' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Arcturus Therapeutics Holdings over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Arcturus Therapeutics' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arcturus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Arcturus Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 15,846,543 | |
| Geometric Mean | 9,414,489 | |
| Coefficient Of Variation | 110.07 | |
| Mean Deviation | 14,407,791 | |
| Median | 6,272,000 | |
| Standard Deviation | 17,441,902 | |
| Sample Variance | 304.2T | |
| Range | 45.5M | |
| R-Value | 0.83 | |
| Mean Square Error | 100.4T | |
| R-Squared | 0.69 | |
| Significance | 0.0001 | |
| Slope | 3,248,082 | |
| Total Sum of Squares | 4259.1T |
Arcturus Current Deferred Revenue History
About Arcturus Therapeutics Financial Statements
Arcturus Therapeutics shareholders use historical fundamental indicators, such as Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Arcturus Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Arcturus Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arcturus Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 47.3 M | 49.7 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcturus Stock Analysis
When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.